[{"NetIncomeLoss_3_Q3_USD":-59115000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":92675000.0,"GainLossOnSaleOfPropertyPlantEquipment_3_Q3_USD":0.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":1000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-108305000.0,"Depreciation_3_Q3_USD":108000.0,"InterestIncomeExpenseNonoperatingNet_3_Q3_USD":437000.0,"InterestIncomeExpenseNonoperatingNet_1_Q3_USD":33000.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q3_USD":7012000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":67931000.0,"AssetsCurrent_0_Q3_USD":234399000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":9153000.0,"AvailableForSaleDebtSecuritiesGrossUnrealizedGain_3_Q3_USD":6000.0,"CommonStockSharesIssued_0_Q3_shares":89554044.0,"StockIssuedDuringPeriodValueIssuedForServices_1_Q3_USD":147000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":108303000.0,"Assets_0_Q3_USD":234595000.0,"ShareBasedCompensation_3_Q3_USD":6044000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":134000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":9153000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"GeneralAndAdministrativeExpense_1_Q3_USD":6643000.0,"IncomeTaxesReceivableNoncurrent_0_Q3_USD":0.0,"ResearchAndDevelopmentExpense_1_Q3_USD":18841000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":-6000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":1000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":-3695000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":0.0,"NumberOfReportableSegments_3_Q3_segment":1.0,"CommonStockValue_0_Q3_USD":90000.0,"ProceedsFromIncomeTaxRefunds_3_Q3_USD":3327000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":17930000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":1383000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-59114000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-25449000.0,"OtherAssetsNoncurrent_0_Q3_USD":0.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":122819000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":76000.0,"Cash_0_Q3_USD":3700000.0,"Liabilities_0_Q3_USD":20009000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":150453000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"ProceedsFromSaleOfProductiveAssets_3_Q3_USD":0.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-542000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-2880000.0,"CommonStockSharesOutstanding_0_Q3_shares":89554044.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":108305000.0,"IncreaseDecreaseInAccruedInterestReceivableNet_3_Q3_USD":112000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-62810000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-25450000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":1847000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-45028000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-539641000.0,"LiabilitiesCurrent_0_Q3_USD":19933000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":1513000.0,"DeferredIncomeTaxesAndTaxCredits_3_Q3_USD":0.0,"AdditionalPaidInCapital_0_Q3_USD":754136000.0,"CashEquivalentsAtCarryingValue_0_Q3_USD":119100000.0,"NumberOfOperatingSegments_3_Q3_segment":1.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":62000.0,"NetIncomeLoss_1_Q3_USD":-25450000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":122819000.0,"AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_3_Q3_USD":5000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":-115000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":108302000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"CommonStockSharesAuthorized_0_Q3_shares":200000000.0,"OperatingIncomeLoss_3_Q3_USD":-63241000.0,"OperatingIncomeLoss_1_Q3_USD":-25484000.0,"IncomeTaxesReceivable_0_Q3_USD":1764000.0,"IncreaseDecreaseInIncomeTaxesReceivable_3_Q3_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3_Q3_pure":0.0,"PreferredStockValue_0_Q3_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":234595000.0,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":6044000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":1847000.0,"OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_1_Q3_USD":1000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":54000.0,"OperatingExpenses_3_Q3_USD":63241000.0,"OperatingExpenses_1_Q3_USD":25484000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-0.87,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.27,"StockholdersEquity_0_Q3_USD":214586000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":45311000.0,"ClassOfWarrantOrRightOutstanding_0_Q3_shares":3164280.0,"Ticker":"ISEE","CIK":"1410939","name":"IVERIC BIO, INC.","OfficialName":"IVERIC bio Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"3","uom":"USD","footnote":"nan","Market Cap":"1851737728.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201103"}]